Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

BADR F AL BAWARDY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1104111509
CMS profile
1077896
Location
NEW HAVEN, CT

General Payments · PY2018–2022

$42,397.92

  • Reported across 34 records
  • CMS publication 2026-01-23

Latest program year · PY2022

$20,021.06

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2022 · sorted by reported total

By paying entity

PY2022 · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $11,916.05 6
E.R. Squibb & Sons, L.L.C. $7,715.00 3
Celgene Corporation $390.01 3

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $182.29 2
PY2020 $2,849.69 3
PY2021 $19,344.88 17
PY2022 $20,021.06 12

Payment records · PY2022 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2022 201820202021 Record-level detail is published for PY2022; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Celgene Corporation $30.00 05/20/2022 Food and Beverage Undisputed 01/23/2026 932877601 CMS
Celgene Corporation $60.01 05/20/2022 Food and Beverage Undisputed 01/23/2026 932877603 CMS
Celgene Corporation $300.00 06/15/2022 Consulting Fee Undisputed 01/23/2026 932877635 CMS
E.R. Squibb & Sons, L.L.C. $125.00 07/19/2022 Food and Beverage Undisputed 01/23/2026 932877569 CMS
E.R. Squibb & Sons, L.L.C. $3,990.00 07/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 932877571 CMS
E.R. Squibb & Sons, L.L.C. $3,600.00 09/13/2022 Consulting Fee Undisputed 01/23/2026 932877573 CMS
Takeda Pharmaceuticals U.S.A., Inc. $883.14 03/22/2022 Travel and Lodging Undisputed 01/23/2026 955598703 CMS
Takeda Pharmaceuticals U.S.A., Inc. $101.60 03/22/2022 Food and Beverage Undisputed 01/23/2026 955598705 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,548.00 03/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 955598707 CMS
Takeda Pharmaceuticals U.S.A., Inc. $125.00 09/15/2022 Food and Beverage Undisputed 01/23/2026 955598709 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,328.31 09/15/2022 Travel and Lodging Undisputed 01/23/2026 955598711 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,930.00 10/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 955598713 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2020, 2021, 2022
Source files
Dataset page · Bulk file · PY2018 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.